<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03308474</url>
  </required_header>
  <id_info>
    <org_study_id>iOM-060331</org_study_id>
    <nct_id>NCT03308474</nct_id>
  </id_info>
  <brief_title>Myeloma Registry Platform (MYRIAM)</brief_title>
  <acronym>MYRIAM</acronym>
  <official_title>Clinical Research Platform for Molecular Testing, Treatment and Outcome of Patients With Multiple Myeloma (Myeloma Registry Platform; MYRIAM)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>iOMEDICO AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsche Studiengruppe Multiples Myelom (DSMM)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>iOMEDICO AG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the project is to set up a national, prospective, longitudinal, multicenter
      cohort study with associated satellites, a tumor registry platform, to document uniform data
      on characteristics, molecular diagnostics, treatment and course of disease, to collect
      patient-reported outcomes and to establish a decentralized biobank for patients with Multiple
      Myeloma in Germany.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MYRIAM is a national, observational, prospective, longitudinal, multicenter cohort study
      (tumor registry platform) with the purpose to record information on the antineoplastic
      treatment of multiple myeloma in Germany. The registry will follow patients for up to five
      years. It will identify common therapeutic sequences and changes in the treatment of the
      disease. At inclusion, data in patient characteristics, comorbidities, tumor characteristics
      and previous treatments are collected. During the course of observation data on all systemic
      treatments, radiotherapies, surgeries, and outcome are documented.

      Health-realted quality of life in patients with multiple myeloma (MyLife) will be evaluated
      for up to five years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 25, 2017</start_date>
  <completion_date type="Anticipated">December 2027</completion_date>
  <primary_completion_date type="Anticipated">December 2026</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Course of treatment (treatment reality)</measure>
    <time_frame>5 years per patient</time_frame>
    <description>Documentation of anamnestic data and therapy sequences</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best Response</measure>
    <time_frame>5 years per patient</time_frame>
    <description>Documentation of response rates per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>5 years per patient</time_frame>
    <description>Documentation of progression-free survival per line of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years per patient</time_frame>
    <description>Documentation of overall survival time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related quality of life (Patient-reported outcome)</measure>
    <time_frame>5 years per patient</time_frame>
    <description>EORTC QLQ-C30 core questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myeloma-specific health-related quality of life (Patient-reported outcome)</measure>
    <time_frame>5 years per patient</time_frame>
    <description>EORTC QLQ-MY20, the myeloma specific module.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (Patient-reported outcome)</measure>
    <time_frame>5 years per patient</time_frame>
    <description>Brief Pain Inventory (BPI)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Routine care as per site standard.</intervention_name>
    <description>Physician's choice according to patient's needs.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients with multiple myeloma (MM) requiring systemic treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  MM requiring systemic (first- or second-line) treatment

          -  Age ≥ 18 years

          -  Written informed consent

               -  Patients participating in the PRO satellite: signing of informed consent and
                  completion of baseline questionnaire before, but not more than eight weeks before
                  the start of respective systemic treatment

               -  Patients not participating in the PRO satellite: signing of informed consent not
                  later than four weeks after start of respective treatment, and not more than
                  eight weeks before the start of respective systemic treatment

          -  Sufficient German language skills for participation in the PRO satellite

        Exclusion Criteria:

          -  No systemic therapy for myeloma

          -  Patients already enrolled in studies that prohibit any participation in other studies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hermann Einsele, Prof MD</last_name>
    <role>Study Chair</role>
    <affiliation>Wuerzburg University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Monika Engelhardt, Prof MD</last_name>
    <role>Study Chair</role>
    <affiliation>Universitätsklinikum Freiburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tobias Dechow, Prof MD</last_name>
    <role>Study Chair</role>
    <affiliation>Onkologie Ravensburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Knauf, Prof MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centrum für Hämatologie und Onkologie Bethanien</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Norbert Marschner, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Praxis für interdisziplinäre Onkologie &amp; Hämatologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martina Jänicke, PhD</last_name>
    <phone>+49 761 15242-0</phone>
    <email>info@iomedico.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Multiple sites all over germany</name>
      <address>
        <city>Multiple Locations</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>iOMEDICO AG</last_name>
      <phone>+49 761 152420</phone>
      <email>info@iomedico.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 25, 2017</study_first_submitted>
  <study_first_submitted_qc>October 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2017</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

